BELLUS Health ends NC-503 diabetes development program following results

LAVAL, QC, May 4 /CNW Telbec/ - BELLUS Health (TSX: BLU) announced today that it will discontinue its NC-503 diabetes development program following the results of the recently completed Phase IIa clinical proof-of-concept study evaluating NC-503 (eprodisate disodium) as a treatment for Type 2 diabetes. The study did not meet its primary efficacy endpoint.

"While we are disappointed that the NC-503 indication for Type 2 Diabetes did not prove to be effective, our decision today enables us to preserve shareholder value and conserve our financial and human resources for projects that we believe have high potential for success," said Roberto Bellini, President and Chief Executive Officer of BELLUS Health.

About NC-503 (eprodisate disodium)

NC-503 (eprodisate disodium, KIACTA(TM)) is a small molecule that is currently being developed for the treatment of AA amyloidosis, a rare disease related to the systemic extracellular deposition of insoluble fibrillar proteins (amyloid) mostly on the kidneys. While eprodisate has been shown to have protective effects on renal function in AA amyloidosis patients in a clinical Phase III study, pre-clinical rodent model data had also suggested that eprodisate had glucose lowering activity and could improve features of metabolic syndrome.

About BELLUS Health

BELLUS Health is a global health company focused on the research and development of products to provide innovative health solutions to address critical unmet medical needs. For further information, please visit

Forward Looking Statements

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business


For further information: For further information: Anne-Marie Durand, NATIONAL Public Relations, (514) 843-2319

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890